1450 Results
Sort By:
Published on November 1, 2017
Scientists at the Albert Einstein College of Medicine in New York recently published research that offers new insights into the role microbiome composition and enzyme activity plays on the likelihood cancer patient will suffer from potentially life-threatening diarrhea following treatment with the chemotherapy agent irinotecan. The research indicates it may…
Published on October 30, 2017
For the first time, say researchers, comprehensive DNA and RNA sequencing of a patient's tumor have been used in a clinical trial to inform real-time treatment for patients with recurring glioblastoma. The Translational Genomics Research Institute (TGen), University of California, San Francisco (UCSF), and the Ivy Foundation Early Phase Clinical…
Published on October 23, 2017
IsoPlexis said today it has won a two-year, $1.8 million Small Business Innovation Research (SBIR) grant from the NIH’s National Cancer Institute (NCI) to develop an automated assay platform and informatics suite for larger clinical trials of cell therapies. IsoPlexis said it would collaborate with UCLA and other top academic…
Published on September 22, 2017
Researchers at the University of California, Berkeley, and Massachusetts General Hospital have identified a key region within the Cas9 protein that governs how accurately CRISPR/Cas9 homes in on a target DNA sequence, and have tweaked it to produce a hyper-accurate gene editor with the lowest level of off-target cutting to…
Published on September 20, 2017
Synpromics says growing global demand has prompted the developer of gene control and synthetic promoter technology to relocate to expanded facilities in Edinburgh, Scotland. The company has moved into more than 5,000 square feet at the Roslin Innovation Centre, based at the University of Edinburgh’s Easter Bush Campus. Synpromics’ new…
Published on September 11, 2017
BioMarker Strategies said today it has won a two-year, $1.98 million Phase II Fast Track Small Business Innovation Research (SBIR) grant from the NIH’s National Cancer Institute (NCI) toward development of a companion diagnostic test toward facilitating therapy selection for patients with non-small cell lung cancer. PathMAP NSCLC is a…
Published on August 30, 2017
Extending noninvasive prenatal screening to all 24 human chromosomes can detect genetic disorders that may explain miscarriage and abnormalities during pregnancy, according to a study by researchers at the National Institutes of Health and other institutions. Because of the way data have been analyzed, typical genomic tests performed during pregnancy…
Published on August 28, 2017
MedGenome said today it has completed a $30 million Series C financing, with the genomics research and diagnostics company directing proceeds toward its biomarker discovery programs and further development of its OncoPept™ suite of cancer immunotherapy biomarker solutions. The financing will allow genomic and biopharma researchers in the U.S. and…
Published on July 3, 2017
Despite the signficant promise of CRISPR to correct the genetic underpinnings of disease, the technology still has signficant risk off-target effects—instances when non-targeted genes are altered. Scientists from The University of Texas at Austin took an important step toward safer gene-editing cures for life-threatening disorders, from cancer to HIV to…
Published on June 30, 2017
Illumina has won FDA approval for its Extended RAS Panel, a next-generation sequencing (NGS) kit for use with the company’s MiSeqDx System to help clinicians identify patients eligible for treatment of metastatic colorectal cancer (mCRC) with Amgen’s marketed drug Vectibix® (panitumumab). “Together with Amgen, we've developed a companion diagnostic test…
Published on June 26, 2017
Biodata gold is all around us, but it is hard to find, distributed as it is in traces throughout a vast biodata landscape, one that has scarcely been explored properly, even as it continues to be reshaped by next-generation sequencing, the effects of which are, well, tectonic. Thus far, biodata…
Published on June 23, 2017
In what Thermo Fisher Scientific officials are calling an “historic, path-breaking event,” the FDA has granted premarket approval to the company’s Oncomine Dx Target Test, which screens tumor samples for biomarkers associated with three FDA-approved drugs for non-small cell lung cancer (NSCLC). The panel-based test evaluates 23 different biomarkers simultaneously and…
Published on June 21, 2017
New research led by a group of investigators from Emory University builds toward the hope of using CRISPR/Cas9 gene editing to alleviate the genetic roots of disease. In research published in the Journal of Clinical Investigation, researchers showed how the CRISPR/Cas9 system could delete part of a gene that produces toxic…
Published on June 14, 2017
Personal Genome Diagnostics said today it won a contract from the U.S. Department of Veterans Affairs (VA) to provide its PlasmaSELECT™ 64 liquid biopsy profiling assay to advanced cancer patients being treated at VA facilities. The value of the contract was not disclosed. PlasmaSELECT will be the first plasma-based genomic profiling…
Published on June 9, 2017
Foundation Medicine and Caris Life Sciences will alert physicians to patients who are eligible for the National Cancer Institute’s Phase II NCI-MATCH (Molecular Analysis for Therapy Choice) study, through separate collaborations announced this week. The companies said they will inform the physicians, who will work from more than 1,100 clinical…